NCT06744075Active, not recruiting
Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma
Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients Treated for B-cell Lymphoma or Hodgkin Lymphoma
Source: ClinicalTrials.gov · Last updated 30 Dec 2025
Brief summary (registry, in English)
This study aims to assess the feasibility of predicting patient outcomes at 1 year and 2 years after the end of first-line treatment using "liquid biopsy" (monitoring of circulating tumor DNA, ctDNA), compared to the currently recommended examination, which is Positon Emission Tomography (PET-CT) imaging at the end of first-line treatment (assessment of therapeutic response using the Deauville score according to the Lugano 2014 criteria). The study will focus on demonstrating the ability of ctDNA clearance to predict 1-year and 2-year outcomes (lymphoma progression or death) in patients treated with first-line therapy for B-cell lymphoma or Hodgkin lymphoma. This could contribute to establishing minimal residual disease clearance as a key endpoint for evaluating the efficacy of therapeutic strategies in future clinical trials and guiding patient management (e.g., de-escalation or intensification strategies, redirection toward immunotherapy, and theranostic approaches).
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 108 (estimated)
- First submitted
- 16 Dec 2024
- Start date
- 24 Dec 2024
- Primary completion date
- 20 Dec 2027
- Lead sponsor
- Centre Henri Becquerel
- Diseases
- Hodgkin lymphoma
- NCT number
- NCT06744075
What you commit to
- Study type: Interventional
- Planned participants: 108
- From 24 Dec 2024 to the primary completion date, 20 Dec 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient who has already started first-line chemotherapy or chemoimmunotherapy for lymphoma treatment (prephase corticosteroid therapy is allowed)
Other
- Pregnant or breastfeeding woman
- Patient enrolled in a clinical trial evaluating an early-phase therapeutic agent (Phase I-II)
- Patient weighing less than 30 kg
- Adult under legal protection measures
- Patient unable to understand the study for any reason or unable to comply with the trial requirements (e.g., language barrier, psychological, or geographic issues).
Who the study is looking for
- Patient aged 18 years or older
- Diagnosed with large B-cell lymphoma (including T-cell/histiocyte-rich B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma), follicular B-cell lymphoma (all grades), mantle cell lymphoma (all variants), marginal zone B-cell lymphoma, or Hodgkin lymphoma (classical Hodgkin lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma)
- Indication for first-line systemic treatment with chemotherapy or chemoimmunotherapy
- Has signed the study-specific informed consent form
- Pre-treatment PET-CT scan performed
- Patient is affiliated with or a beneficiary of a health insurance plan
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hôpital Jacques Monod Coordinator of this site? Confirm its status | Montivilliers | France | Unknown status |
| Centre Henri Becquerel Coordinator of this site? Confirm its status | Rouen | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.